Search our site
Contact us for epilepsy information and support

Categories

Medicinal Cannabis and Epilepsy

Medicinal Cannabis and Epilepsy Syndromes

Medicinal Cannabis Studies

Medicinal Cannabis in Australia

Real-Life Experience With Purified Cannabidiol Treatment for Refractory Epilepsy: A Multicenter Retrospective Study

Purified CBD is well-tolerated and effective in reducing seizure frequency in children and young adults with DRE. Pediatric Neurology. Jan 2024

Medicinal Cannabis and Epilepsy

Potential Drug Interactions with Cannabinoids in Selected Chronic Diseases: Epilepsy, Autism Spectrum Disorders, Oncology, Multiple Sclerosis and Pain

This review critically summarizes the potential impact of cannabinoids in concomitance with other drugs in the following chronic diseases as Epilepsy, Autism Spectrum Disorders, Oncology, Multiple Sclerosis, and Chronic Pain Medicine and Pharmacology. Feb 2024

Medicinal Cannabis and Epilepsy

Multifaceted targets of cannabidiol in epilepsy: Modulating glutamate signaling and beyond

Computers in Biology and Medicine 2024

Medicinal Cannabis and Epilepsy

Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations

Chemico-Biological Interactions 2024

Medicinal Cannabis and Epilepsy

Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis

Epilepsy & Behaviour 2020

Medicinal Cannabis and Epilepsy

Oral liquid cannabidiol (Epidyolex) for Dravet syndrome

NPS Medicinewise 2021

Medicinal Cannabis and Epilepsy

Cannabis-based products for pediatric epilepsy: A systematic review

Epilepsia 2019

Medicinal Cannabis and Epilepsy

Clinical Outcome Data of Children Treated with Cannabis-Based Medicinal Products for Treatment Resistant Epilepsy

Neuropediatrics, 2023

Medicinal Cannabis and Epilepsy

Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis

CBD treatments were effective compared with placebo, regardless of the dose administered and there was a greater tendency for side-effects in short-term treatment compared with long-term treatment.

 

Medicinal Cannabis and Epilepsy

Food effect on pharmacokinetics of oral cannabidiol

Evaluates the pharmacokinetics of a purified oral cannabidiol (CBD) capsule administered with and without food in adults with refractory epilepsy. Epilepsia Sept 2019

Medicinal Cannabis and Epilepsy

Real-Life Experience With Purified Cannabidiol Treatment for Refractory Epilepsy: A Multicenter Retrospective Study

Pediatric Neurology 2024

Medicinal Cannabis and Epilepsy Syndromes

Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial

Epilepsia 2022

Medicinal Cannabis and Epilepsy Syndromes

Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trial

Epilepsia 2021

Medicinal Cannabis and Epilepsy Syndromes

Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome

Long-term treatment with add-on CBD in patients with DS produced sustained seizure reductions, with no new safety concerns. Neurology April 2020

Medicinal Cannabis and Epilepsy Syndromes

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Medicinal Cannabis and Epilepsy Syndromes

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex

In this study, both cannabidiol dosages were equally efficacious in reducing tuberous sclerosis complex–associated seizures compared with placebo, but the smaller dosage led to fewer adverse events.

Medicinal Cannabis and Epilepsy Syndromes

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

The Annuals of Pharmacotherapy. 2019

Medicinal Cannabis and Epilepsy Syndromes

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

Epilepsia October 2019

Medicinal Cannabis and Epilepsy Syndromes

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study

Thiele E, Marsh E, Mazurkiewicz‐Beldzinska M, Halford JJ, Gunning B, Devinsky O, Checketts D, Roberts C

Epilepsia Mar 2019 (Article)

Medicinal Cannabis and Epilepsy Syndromes

Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis

Lattanzi S, Brigo F, Cagnetti C, Trinka E and Silvestrini M

CNS Drugs Oct 2018 (Abstract)

Medicinal Cannabis and Epilepsy Syndromes

Potential Drug Interactions with Cannabinoids in Selected Chronic Diseases: Epilepsy, Autism Spectrum Disorders, Oncology, Multiple Sclerosis and Pain

This review critically summarizes the potential impact of cannabinoids in concomitance with other drugs in the following chronic diseases as Epilepsy, Autism Spectrum Disorders, Oncology, Multiple Sclerosis, and Chronic Pain Medicine and Pharmacology. Feb 2024

Medicinal Cannabis Studies

Real-Life Experience With Purified Cannabidiol Treatment for Refractory Epilepsy: A Multicenter Retrospective Study

Pediatric Neurology 2024

Medicinal Cannabis Studies

Multifaceted targets of cannabidiol in epilepsy: Modulating glutamate signaling and beyond

Computers in Biology and Medicine 2024

Medicinal Cannabis Studies

Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Scientific Reports, Dec 2021

Medicinal Cannabis Studies

Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease

International Journal of Molecular Science. August 2021

Medicinal Cannabis Studies

Overlapping patterns of recreational and medical cannabis use in a large community sample of cannabis users

Comprehensive Psychiatry

Volume 102, October 2020

Medicinal Cannabis Studies

Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey

Accident Analysis & Prevention

Volume 148, December 2020

Medicinal Cannabis Studies

Medical cannabis use in the Australian community following introduction of legal access

Harm Reduction Journal (2020)

Medicinal Cannabis Studies

The safety, tolerability and pharmacokinetics of a cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. Phase 1 trial.

No serious adverse events reported. The most common related adverse side effects were sleepiness, sedation and altered mood, and these were all mild or moderate in severity. BJCP-MediCabilis Phase I study

Medicinal Cannabis Studies

Practical considerations in medical cannabis administration and dosing

European Journal of Internal Medicine. March 2018

Medicinal Cannabis Studies

Oral liquid cannabidiol (Epidyolex) for Dravet syndrome

NPS Medicinewise 2021

Medicinal Cannabis in Australia

Medicinal Cannabis Guidance and Resources for Health Professionals to Inform Clinical Decision Making

Clinical Therapeutics, Jun 2023

Medicinal Cannabis in Australia

Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey

Accident Analysis & Prevention

Volume 148, December 2020

Medicinal Cannabis in Australia

Epidyolex Consumer Medical Information (Australia)

Medicinal Cannabis in Australia

Medical Cannabis: What you need to know

Information and resources for consumers and health professionals.

NPS Medicinewise 2020

Medicinal Cannabis in Australia

Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms

Social Science & Medicine 2019

Medicinal Cannabis in Australia

Medical Cannabis: What’s the Evidence?

Interview with Dr Norman Swan

Medicinal Cannabis in Australia

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

Epilepsia October 2019

Medicinal Cannabis in Australia

Survey of Australian psychiatrists’ and psychiatry trainees’ knowledge about and attitudes towards medicinal cannabinoids

Jacobs NI, Montebello M, Monds LA, Lintzeris N

Australasian Psychiatry Feb 2019 (Abstract)

Medicinal Cannabis in Australia

Medicinal cannabis in Australia,2016 : the Cannabis as Medicine Survey (CAMS-16)

Nicholas Lintzeris, Jessica Driels, Natalie Elias, Jonathon C Arnold, Iain S McGregor and David J Allsop

Medical Journal of Australia Sep 2018 (Article)

Medicinal Cannabis in Australia

Coming Soon

Coming Soon


Created with Visual Composer